Assessment of Heart Rate Variability for Predicting Obstructive Sleep Apnea in Patients With Hypertension
This study aims to investigate the relationship between hypertension and obstructive sleep apnea (OSA) using heart rate variability (HRV) as a non-invasive biomarker of autonomic nervous system function. Hypertensive patients at high risk for OSA will undergo 24-hour Holter electrocardiogram monitoring to assess HRV parameters, along with overnight polysomnography (PSG) to determine OSA severity. The study will analyze the association between HRV indices and the apnea-hypopnea index (AHI), and develop predictive…
Conditions studied
Obstructive Sleep Apnea, Hypertension
About this study
This study aims to investigate the relationship between hypertension and obstructive sleep apnea (OSA) using heart rate variability (HRV) as a non-invasive biomarker of autonomic nervous system function. Hypertensive patients at high risk for OSA will undergo 24-hour Holter electrocardiogram monitoring to assess HRV parameters, along with overnight polysomnography (PSG) to determine OSA severity. The study will analyze the association between HRV indices and the apnea-hypopnea index (AHI), and develop predictive models using machine learning techniques. In addition, patients diagnosed with OSA will be followed after treatment, and changes in HRV and blood pressure will be evaluated to assess treatment effects and autonomic function recovery. The results of this study may provide a cost-effective and clinically applicable approach for early detection, risk stratification, and management of OSA in patients with hypertension.
Interventions
- Diagnostic Test: Polysomnography — Overnight polysomnography (PSG) will be performed to evaluate sleep parameters and determine the severity of obstructive sleep apnea.
Primary outcomes
- Prediction of OSA Severity Using Heart Rate Variability (Baseline (at time of HRV monitoring and polysomnography))
Eligibility information
Study locations
- Kaohsiung Armed Forces General Hospital, Kaohsiung City, Kaohsiung Taiwan
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.